Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity.
The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing.
SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy ® (semaglutide 2.4mg) in Singapore.
Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia 1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.
The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake 1. This mechanism supports weight loss when combined with sustainable lifestyle changes.
The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity 2 - 4, a condition associated with more than 200 health complications 5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease 6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription.
Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, "Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity"
Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week 7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management.
Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said "With treatments like Wegovy ® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes."
References:
Wegovy Singapore Prescribing Information, February 2025
Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.
World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/
Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html.
World Health Organization. (2024). Obesity and overweight. WHO.https://www.who.int/news-room/factsheets/detail/obesity-and-overweight As accessed on 22nd May 2025.
Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. https://doi.org/10.3389/fpubh.2023.1082581
Hashtag: #NovoNordisk #Wegovy
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
For more information, visit novonordisk.sg.
Novo Nordisk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
8 hours ago
- Zawya
DBS Launches Gen AI-Powered Coaching Tool to Future Proof Its Workforce
HONG KONG SAR - Media OutReach Newswire - 24 July 2025 - DBS announced today that it is democratising coaching for its workforce with the launch of iCoach, a Generative AI-powered (Gen AI) platform developed in collaboration with Marshall Goldsmith, one of the world's top executive coaches. While most corporations reserve coaching[1] for their top executives or high potential talent, DBS believes that employees at all levels would benefit from coaching by receiving expert advice on career development as well as topical issues such as work-life balance, personal and small team leadership, or mental wellness. However, the main challenge has always been scaling coaching in an efficient and cost-effective manner – coaching is usually done on a one-to-one basis and can be costly. With the advent of Gen AI, DBS saw an opportunity to leverage the technology to overcome these challenges, enabling the bank to avail coaching to employees across its network. Lee Yan Hong, Head of Group Human Resources, DBS, said, "As the world of work continues to evolve, building career resilience has become more important than ever. At DBS, we are committed to helping our people thrive by equipping them with future-ready capabilities through our comprehensive Triple E framework – Education, Exposure and Experience. iCoach is a powerful new addition that complements these efforts, leveraging Gen AI to offer personalised, on-demand career guidance to help every employee confidently navigate and grow in the future of work." Betty Lam, Head of Human Resources, DBS Hong Kong, said, "DBS continues to entrench our standing as a Responsible AI leader and bring our employees along this responsible AI journey where AI is used ethically and effectively. iCoach is a powerful tool that allows our employees to focus on personal and career growth. At the same time, we also encourage our employees to equip themselves with the necessary AI skills, which will be crucial for our collective success." iCoach's knowledge base was developed in partnership with Marshall Goldsmith, a leading coaching expert with over four decades of experience working with top CEOs and executives, including those from Fortune 500 companies. Dr Goldsmith was inducted by Thinkers50[2] into its Hall of Fame in 2018 and is the only two-time Thinkers50 #1 Leadership Thinker in the World. He was also the inaugural winner of the Lifetime Award for Leadership by the Harvard Institute of Coaching. iCoach is always-on and available 24/7 to provide employees with just-in-time personalised career guidance. It is tailored to each employee, drawing on the context of the bank's roles, functions and internal mobility pathways to deliver relevant and actionable career advice. Data from International Coaching Federation and Better Up Career Coaching showed 70% of people in organisations who underwent coaching benefitted from improved work performance, relationships and more effective communication skills. 80% of people who received coaching reported increased self-confidence. iCoach further reinforces the bank's commitment to upskilling its employees and building career resilience, and complements other DBS initiatives including: iGrow, an AI / machine learning-powered platform that offers personalised career advice by matching employees to tailored learning and job opportunities based on their career and training history. DBS Mentoring Programme, which connects employees with leaders and peers, enabling them to gain practical guidance, career insights and support at critical points in their professional growth. DBS Learning Hub, which provides employees with more than 10,000 curated courses, to learn and pick up new skills. Be My Guest Programme, where employees have the opportunity to participate in job shadowing, workshops and projects across departments. Last year, over 4,000 such opportunities were taken up by employees. The bank's commitment to supporting employees with career development has contributed to its recognition as an employer of choice. In 2025, DBS was ranked first in TIME's 500 Best Companies in Asia Pacific, while in 2024, the bank was named among Forbes World's Best Employers. In Hong Kong, DBS Hong Kong was also recognised at the "Bloomberg Businessweek - Financial Institutions 2025 Awards", winning the "Training Academy – Excellence Performance" and "Training Program of the Year – Outstanding Performance" awards. Additionally, DBS Hong Kong was honoured with the "Employer of the Year", "HR Team of the Year", and the "Grand Award of Recruitment" at the Jobsdb Hong Kong HR Awards 2024/25. [1] Coaching focuses on achieving specific, short-term goals through structured guidance, while mentoring emphasises long-term personal and professional growth through a supportive relationship. For more info here. [2] Thinkers50 is the world's pre-eminent global ranking of management thinkers and has been described by The Financial Times as "the Oscars of management thinking". Hashtag: #DBS The issuer is solely responsible for the content of this announcement. About DBS DBS is a leading financial services group in Asia with a presence in 19 markets. Headquartered and listed in Singapore, DBS is in the three key Asian axes of growth: Greater China, Southeast Asia and South Asia. The bank's "AA-" and "Aa1" credit ratings are among the highest in the world. Recognised for its global leadership, DBS has been named " World's Best Bank" by Global Finance, " World's Best Bank" by Euromoney and " Global Bank of the Year" by The Banker. The bank is at the forefront of leveraging digital technology to shape the future of banking, having been named " World's Best Digital Bank" by Euromoney and the world's " Most Innovative in Digital Banking" by The Banker. In addition, DBS has been accorded the " Safest Bank in Asia" award by Global Finance for 16 consecutive years from 2009 to 2024. DBS provides a full range of services in consumer, SME and corporate banking. As a bank born and bred in Asia, DBS understands the intricacies of doing business in the region's most dynamic markets. DBS is committed to building lasting relationships with customers, as it banks the Asian way. Through the DBS Foundation, the bank creates impact beyond banking by supporting social enterprises: businesses with a double bottom-line of profit and social and/or environmental impact. DBS Foundation also gives back to society in various ways, including equipping communities with future-ready skills and building food resilience. With its extensive network of operations in Asia and emphasis on engaging and empowering its staff, DBS presents exciting career opportunities. For more information, please visit DBS Hong Kong
Zawya
2 days ago
- Zawya
Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins
Black Crystal Roselle Anthocyanin Levels Surge 17.7x — Wel-Bloom Biotech Elevates Taiwan's Global Ingredient Competitiveness Black Crystal Roselle Shakes Up the Anthocyanin Market with 17.7x Natural Concentration Taiwan's Black Crystal Roselle Emerges as a Key Player in the Anthocyanin and Health Markets Anthocyanin Levels Surge in Black Crystal Roselle — Spotlight on Key Ingredient Wel-ROS6 Wel-ROS6 in Black Crystal Roselle Raises the Bar for Health Supplements TAIPEI, TAIWAN - Media OutReach Newswire - 22 July 2025 - Taiwan's leading jelly supplement manufacturer, Wel-Bloom Biotech, recently co-hosted an anthocyanin-focused seminar with LEARN EATiNG, one of the most renowned nutritionist teams in Taiwan. The event highlighted trending international ingredients alongside Taiwan's own Black Crystal Roselle. Attracting around 300 nutrition professionals both online and onsite, the seminar reflected strong industry interest and high expectations for the future of anthocyanin innovation. In recent years, the health supplement market has seen rapid growth, accompanied by a shift in consumer priorities. Today's consumers increasingly believe that "choosing the right ingredients matters more than simply taking more," a mindset that is driving innovation in ingredient formulation. According to the 2024 Top 30 Dietary Trends Report, there is growing interest in the synergistic effects of ingredient combinations. For instance, pairing anthocyanins with fish oil offers comprehensive support for overall health, while combining them with collagen enhances beauty and skin wellness. The Black Crystal Roselle, grown locally in Taiwan, contains naturally high levels of anthocyanins and has recently drawn growing interest in the health supplement field for its promising nutritional potential. As one of the keynote speakers, Wel-Bloom Biotech introduced Wel-ROS6®—a proprietary botanical ingredient derived from Black Crystal Roselle. Developed using triple-patented technology, it is cultivated through natural farming methods and smallholder contract farming to ensure consistent quality and traceability. Laboratory data shows that Wel-ROS6® contains 17.7 times more total anthocyanins than standard commercial roselle. Additionally, total phenolic acids and flavonoids are elevated by 1.9 times and 1.3 times, respectively—highlighting its rich phytochemical profile and high functional value. (See Note 1) The event also featured the Food Industry Research and Development Institute's newly proposed "Food Value Equation": Value = (Sensory Perception × Functional Technology × User Experience) × Amplification Multiplier. This formula highlights the importance of balancing sensory appeal, technological innovation, and user experience—emphasizing that all three elements are essential to creating meaningful value in food products. To meet growing consumer demands for convenience and palatability in health supplements, product development is increasingly focused on factors such as absorption efficiency, flavor optimization, and sustainable sourcing. The rise of "tasty" health products reflects a major trend in preventive wellness—perfectly aligned with today's mindset of "eating less, supplementing smarter." Through its one-stop CDMO (Contract Development and Manufacturing Organization) services, Taiwan's local agriculture can now be transformed from raw materials into globally market-ready products that seamlessly integrate into everyday life. Wel-ROS6®, backed by the support of over 300 health professionals, will be featured alongside other cutting-edge botanical ingredients at the 2025 BIO Asia–Taiwan Exhibition and Vitafoods Asia. We warmly invite you to visit our booth and explore partnership opportunities with Wel-Bloom Biotech to co-create the next generation of best-selling health supplements. Note 1: Testing commissioned to the Food Industry Research and Development Institute: Total phenolic content: Measured using the Folin–Ciocalteu colorimetric assay. Total flavonoid content: Measured using the AlCl₃–NaNO₂–NaOH colorimetric method (also known as the Aluminum chloride colorimetric assay). Independent testing by the Forecast Research Lab: Anthocyanins (Delphinidin chloride, Cyanidin chloride): Quantified using HPLC analysis Total anthocyanins: Measured by the pH differential method Hashtag: #Welbloom #Wel-ROS6 #BlackCrystalRoselle The issuer is solely responsible for the content of this announcement. Welbloom Bio-Tech
Zawya
2 days ago
- Zawya
ADIA to invest $200mln in India's $6.6bln medical device firm Meril
The Abu Dhabi Investment Authority (ADIA) plans to invest $200 million in the Indian medical devices company, Micro Life Sciences Private Limited (Meril). A wholly-owned subsidiary of ADIA has entered into an agreement for an approximate 3% stake in Meril. The investment values the Gujarat-based Meril at $6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Founded by the Bilakhia Group, Meril operates across multiple specialties including cardiovascular, structural heart, orthopaedics, and surgical robotics. ADIA, which established a subsidiary at the Gujarat International Finance Tec-City (GIFT City) last October with plans to set up a $4-$5 billion fund in the special economic zone, has been increasing its India investments over the past year, including in healthcare and pharmaceuticals. Earlier, ADIA acquired a 3% stake in Intas Pharmaceuticals, for approximately $250–$270 million, which valued the Indian firm at around $8.5 billion. The Abu Dhabi sovereign wealth fund also emerged as a key investor in India's Akums Drugs and Pharmaceuticals July IPO, allocating 500 million rupees ($6 million), and representing 6.03% of the anchor investment portion. (Writing by Bindu Rai, editing by Seban Scaria)
